(Reuters) - Contract drug manufacturer Thermo Fisher Scientific ( TMO ) said on Tuesday it will buy Solventum's ( SOLV ) purification and filtration business for about $4.1 billion.

The deal is expected to complement Thermo's bioproduction business, which helps with the drug development process.

The transaction is expected to be completed by the end of 2025.

Shares of Solventum ( SOLV ) rose 2% in premarket trading.